Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D A Tate

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Southern Medical Journal|January 1, 1989
Coronary thrombolysis in rural hospitalsD A Tate, W W Rowe, R J Simpson, et al.
Thrombosis Research|August 1, 1996
Variable influence of heparin and contrast agents on platelet function as assessed by the in vitro bleeding timeL G Melton, G J Dehmer, D A Tate, et al.
The American Journal of Cardiology|July 30, 1999
Effects of an ionic and nonionic contrast agent on von Willebrand factor assessed during coronary angiographyG J Dehmer, T C Nichols, S Li, et al.
The American Journal of Cardiology|May 1, 1997
Absence of human herpesvirus 8 genomes in coronary atherosclerosis in immunocompetent patientsD Ye, T C Nichols, G J Dehmer, et al.
Circulation|November 1, 1996
Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humansG J Dehmer, R A Lange, D A Tate, et al.
The American Journal of Cardiology|December 15, 1990
Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarctionS D Bleich, T C Nichols, R R Schumacher, et al.
American Heart Journal|August 5, 2000
Effect of sex, hemodynamics, body size, and other clinical variables on the corrected thrombolysis in myocardial infarction frame count used as an assessment of coronary blood flowB A Faile, J A Guzzo, D A Tate, et al.
The American Journal of Cardiology|October 29, 2000
Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failureE N Deliargyris, R J Raymond, T C Theoharides, et al.
The American Journal of Cardiology|March 15, 1994
Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase)D R Musselman, D A Tate, B J Oberhardt, et al.
Archives of Internal Medicine|July 1, 1989
Nonemergent cardiac catheterization and risk-stratified revascularization following thrombolytic therapy for acute myocardial infarction. A critical analysis of therapy in the community setting. University of North Carolina Cardiology ConsortiumW W Rowe, R J Simpson, D A Tate, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Southern Medical Journal|January 1, 1989
Coronary thrombolysis in rural hospitalsD A Tate, W W Rowe, R J Simpson, et al.
Thrombosis Research|August 1, 1996
Variable influence of heparin and contrast agents on platelet function as assessed by the in vitro bleeding timeL G Melton, G J Dehmer, D A Tate, et al.
The American Journal of Cardiology|July 30, 1999
Effects of an ionic and nonionic contrast agent on von Willebrand factor assessed during coronary angiographyG J Dehmer, T C Nichols, S Li, et al.
The American Journal of Cardiology|May 1, 1997
Absence of human herpesvirus 8 genomes in coronary atherosclerosis in immunocompetent patientsD Ye, T C Nichols, G J Dehmer, et al.
Circulation|November 1, 1996
Randomized trial of recombinant platelet factor 4 versus protamine for the reversal of heparin anticoagulation in humansG J Dehmer, R A Lange, D A Tate, et al.
The American Journal of Cardiology|December 15, 1990
Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarctionS D Bleich, T C Nichols, R R Schumacher, et al.
American Heart Journal|August 5, 2000
Effect of sex, hemodynamics, body size, and other clinical variables on the corrected thrombolysis in myocardial infarction frame count used as an assessment of coronary blood flowB A Faile, J A Guzzo, D A Tate, et al.
The American Journal of Cardiology|October 29, 2000
Sites of interleukin-6 release in patients with acute coronary syndromes and in patients with congestive heart failureE N Deliargyris, R J Raymond, T C Theoharides, et al.
The American Journal of Cardiology|March 15, 1994
Differences in clot lysis among patients demonstrated in vitro with three thrombolytic agents (tissue-type plasminogen activator, streptokinase and urokinase)D R Musselman, D A Tate, B J Oberhardt, et al.
Archives of Internal Medicine|July 1, 1989
Nonemergent cardiac catheterization and risk-stratified revascularization following thrombolytic therapy for acute myocardial infarction. A critical analysis of therapy in the community setting. University of North Carolina Cardiology ConsortiumW W Rowe, R J Simpson, D A Tate, et al.
Pageof 3